会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • 신규 저분자화 콘드로이틴황산 및 그 용도
    • 具有降解分子量的新型磺酸钠及其用途
    • KR1020100074246A
    • 2010-07-01
    • KR1020107009715
    • 2008-10-01
    • 세이가가쿠 고교 가부시키가이샤
    • 고지마가즈히로고토유키오마에다히로시
    • C08B37/08A61K31/737A61P7/08
    • A61M1/287A61K31/726A61K31/737C08B37/0069C08J3/28C08J2305/08C08K3/02C08K3/08C08K5/09C08L5/08
    • It is intended to provide a chondroitin sulfate having a decreased molecular weight which is useful as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide of glucose as an osmotic substance or is useful as an osmotic substance in a peritoneal dialysis fluid. The chondroitin sulfate having a decreased molecular weight of the invention as a resolution means is characterized in that it has a weight average molecular weight of from 1000 to 20000 and comprises a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total.-[4GlcAF1-3GalNAcF1]-] In the formula, GlcA represents a D-glucuronic acid residue; GalNAc represents a N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and indicates that a group at the 6th position in the monosaccharide residue is sulfated.
    • 旨在提供具有降低的分子量的硫酸软骨素,其可用作由长期使用含有葡萄糖或葡萄糖多糖作为渗透物质的腹膜透析液引起的腹膜障碍的抑制剂,或可用作渗透性 物质在腹膜透析液中。 具有本发明分子量降低的分解度的硫酸软骨素的特征在于其具有1000至20000的重均分子量,并且包含由以下结构式表示的构成的二糖单元,其含量为65% 〜[4GlcAF1-3GalNAcF1] - ]在式中,GlcA表示D-葡萄糖醛酸残基; GalNAc代表N-乙酰基-D-半乳糖胺残基; β1-3代表β1-3糖苷键; β1-4代表β1-4糖苷键; 表示在单糖残基中第6位的基团被硫酸化。